Abstract:Background: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation.Methods: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48-72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor-A (VEGF-A) and estrogen receptor-alpha (ER-alpha), by application of several in vitro assays, such as methyl thiazolyl tetrazolium (MTT), reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, enzyme-linked immunosorbent assay (ELISA) and Western blotting. Also, the cell population's response to external estrogen was investigated by in vivo experiments. HemSCs and human umbilical vein endothelial cells (HUVECs) were mixed and injected subcutaneously into 20 flank of BALB/ c-nu mice, which were randomly divided into 5 groups based on different E2 treatment doses (0, 0.01, 0.1 and 1 mg, respectively), 0.1 mg dimethyl sulfoxide (DMSO) as control. Each group of mice were treated intramuscularly every week, then 2 and 4 weeks later, the subcutaneous implants were harvested and evaluated the tumor tissues with microvessel density (MVD) assay and immunohistochemistry.Results: The study demonstrated that application of E2 increased the expression of FGF2, VEGF-A, and ER-alpha in HemSCs with the optimal concentration from 10(-9) to 10(-5) M. Two-week treatment of E2 promoted expression of VEGF-A and FGF2 in HemSCs culture. Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. In the grafts, mean MVD was markedly increased.Conclusion: The results suggested that E2 promotes angiogenesis via combination with ER-alpha to up-regulate the expression of VEGF-A in HemSCs, promoting proliferation of IHs. These findings provide critical insight into the potential mechanisms of E2 action on IHs.

Cell Fate Regulation During the Development of Infantile Hemangioma

Biology of Infantile Hemangioma

Stem cell in infantile hemangioma

KLF2 Orchestrates Pathological Progression of Infantile Hemangioma through Hemangioma Stem Cell Fate Decisions

The role of multipotential stem cells in human infantile hemangioma

Signaling pathways in the development of infantile hemangioma

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

Infantile haemangioma: a complicated disease.

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

Infantile hemangioma: the common and enigmatic vascular tumor

Insights into the mechanisms of angiogenesis in infantile hemangioma

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities

Non-coding RNA in infantile hemangioma

Role Of Endothelial-Mesenchymal Transition In The Tumorigenesis Of Infantile Hemangioma

Progress In The Treatment Of Infantile Hemangioma

Estrogen-Mediated Hemangioma-Derived Stem Cells Through Estrogen Receptor-Alpha For Infantile Hemangioma

Contribution of skin trauma to infantile skin hemangioma.

Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.

Shift of Treatment Algorithm and Methods for Infantile Hemangiomas

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening